Frontiers in Pharmacology (Aug 2021)

cGAS-STING Signaling Pathway and Liver Disease: From Basic Research to Clinical Practice

  • Bangjie Chen,
  • Xianyue Rao,
  • Xinyi Wang,
  • Zhipan Luo,
  • Jianpeng Wang,
  • Shuyan Sheng,
  • Yuchen Liu,
  • Ning Zhang,
  • Shiyu Jin,
  • Haosong Chen,
  • Chenyu Sun,
  • Tao Xu,
  • Tao Xu,
  • Yingying Du

DOI
https://doi.org/10.3389/fphar.2021.719644
Journal volume & issue
Vol. 12

Abstract

Read online

The cGAS-STING signaling pathway is an autoimmune inflammatory pathway that can trigger the expression of a series of inflammatory factors represented by type 1 interferon. Recent studies have found that the cGAS-STING signaling pathway played a significant role in liver physiology and was closely related to the progress of liver diseases. For example, activating the cGAS-STING signaling pathway could significantly inhibit hepatitis B virus (HBV) replication in vivo. Moreover, the cGAS-STING signaling pathway was also closely associated with tumor immunity in hepatocellular carcinoma (HCC). This review summarized the role of the cGAS-STING signaling pathway in several common liver diseases, especially the current application of the cGAS-STING signaling pathway in liver disease treatment, and prospected its future research, which provided a new idea for understanding and treating liver diseases.

Keywords